Search results for "seroconversion"

showing 10 items of 40 documents

GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults

2021

AbstractSafe and effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed to control the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand. We have developed a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized pre-fusion SARS-CoV-2 Spike protein, named GRAd-COV2. We aimed to assess the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group. To this purpose, a phase 1, dose-escalation, open…

Pediatricsmedicine.medical_specialtybiologybusiness.industryImmunogenicityGorillaVaccinationRegimenAntigenbiology.animalPandemicbiology.proteinmedicineAntibodySeroconversionbusiness
researchProduct

A combination vaccine against measles, mumps, rubella and varicella.

2008

A new combination vaccine against measles, mumps, rubella and varicella (MMRV) from GlaxoSmithKline Biologicals has recently been approved in Europe. It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella. This review presents a summary of the development of this MMRV vaccine from published clinical studies. Seroconversion rates and antibody titers after the first and second dose are similar to those observed after concomitant administration of the MMR and varicella vaccines. Furthermore, the clinical profile of this combination vaccine, in terms of injection- site and general tolerability, is similar to that of the component vacci…

Pediatricsmedicine.medical_specialtymedicine.vaccineMeaslesRubellaChickenpox VaccineChickenpoxmedicineHumansPharmacology (medical)Vaccines CombinedSeroconversionChildMumpsImmunization ScheduleRubellaPharmacologyAttenuated vaccineMMRV vaccinebusiness.industryVaccinationAntibody titerInfantGeneral Medicinemedicine.diseaseVirologyVaccinationTolerabilityChild PreschoolbusinessMeasles-Mumps-Rubella VaccineMeaslesDrugs of today (Barcelona, Spain : 1998)
researchProduct

Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults.

2010

International audience; In the present pilot study, intradermal ID delivery systems with a BD microneedle from 1 to 3mm in length, and epidermal delivery (BD skin abrader) through abraded skin surface relative to standard intramuscular injection were evaluated. Circulating neutralizing antibodies were measured against the rabies virus after the Vero cells rabies vaccine was administered at D0, D7, D21 and D49. This clinical evaluation in 66 healthy volunteers shows that ID delivery using BD microneedle technology of 1/4 the IM antigen dose is safe, efficient and reliable, resulting in a protective seroconversion rate. In contrast, the epidermal delivery route did not produce an immune respo…

Pilot Projectsmedicine.disease_causeAntibodies ViralMESH: Antibodies Neutralizing0302 clinical medicineRabies vaccine030212 general & internal medicineViralMononegaviralesNeutralizingSkin0303 health sciencesIntramuscularbiologyintegumentary systemVaccinationMESH: Rabies VaccinesMESH: Injections Intramuscular3. Good healthVaccinationInfectious DiseasesNeedlesMESH: Young Adult[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMolecular MedicineFemalemedicine.drugAdultInjections IntradermalAdolescentRabiesInjections IntramuscularAntibodiesInjections03 medical and health sciencesYoung AdultMESH: RabiesMESH: SkinIntradermalmedicineHumansSeroconversionLyssavirus030304 developmental biologyMESH: AdolescentMESH: Injections IntradermalMESH: HumansGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryRabies virusPublic Health Environmental and Occupational HealthMESH: AdultMESH: VaccinationRhabdoviridaebiology.organism_classificationmedicine.diseaseMESH: Pilot ProjectsVirologyAntibodies NeutralizingRabies VaccinesMESH: NeedlesImmunologyRabiesbusinessMESH: FemaleMESH: Antibodies Viral
researchProduct

Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipien…

2009

The current recommendations for active immunization after stem cell transplant (SCT) include 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7) from 3 months after transplant, followed by a 23-valent polysaccharide pneumococcal vaccine (PPV23). However, until now, the immune response to PPV23 after PCV7 has not been assessed after SCT. In the EBMT IDWP01 trial, 101 patients received 1 dose of PPV23 at 12 or 18 months, both after 3 doses of PCV7. The efficacy of PPV23 was assessed 1 month later and at 24 months after transplant by the pneumococcal serotype 1 and 5 antibody levels. Serotype 1 and 5 are not included in PCV7. Although the geometric mean concentrations were significantly …

SerotypeAdultMaleHeptavalent Pneumococcal Conjugate VaccineAdolescentActive immunizationcomplex mixturesPneumococcal conjugate vaccinePneumococcal VaccinesYoung Adultstomatognathic systemConjugate vaccineHeptavalent Pneumococcal Conjugate VaccinemedicineHumansTransplantation HomologousSeroconversionChildTransplantationGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthPneumococcal vaccineMiddle AgedAntibodies BacterialAllogeneic stem cell transplantationVaccinationInfectious DiseasesStreptococcus pneumoniaePneumococcal vaccineImmunologyMolecular MedicineFemalebusinessPneumococcal infectionmedicine.drugStem Cell Transplantation
researchProduct

Modification of the immune response against hepatitis B virus by the human immunodeficiency virus.

1989

Hepatitis B virus and the human immunodeficiency virus are similarly transmitted. Individuals with preexisting HIV infection have a higher chance to become HBsAg carriers than do anti-HIV negative persons. Cytotoxic T cells with specificity for HBcAg, that are under the control of HBcAg-specific helper T cells, are responsible for liver injury. There is good evidence that HIV infection lowers inflammatory activity, is associated with milder liver histology, high levels of viral replication and low seroconversion rates. In addition interferon alpha therapy is less effective in anti-HIV positive subjects. The immune response against HBsAg is helper T-cell dependent and vaccination against hep…

Viral Hepatitis VaccinesHBsAgHepatitis B virusImmunologyAlpha interferonmedicine.disease_causeImmune systemRheumatologyHIV SeropositivitymedicineImmunology and AllergyHumansSeroconversionHepatitis ChronicHepatitis B virusImmunity Cellularbusiness.industryvirus diseasesHIVT-Lymphocytes Helper-InducerHepatitis Bmedicine.diseaseVirologyHBcAgImmunologyCarrier StateInterferon Type IbusinessViral loadT-Lymphocytes CytotoxicRheumatology international
researchProduct

Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure

1990

Hepatitis B vaccination and interleukin-2 receptor expression in chronic renal failure. Only 50 to 60% of dialysis patients develop anti-HBs antibodies following hepatitis b vaccination. The nonre-sponder state correlates with impaired monocyte function, decreased interleukin-2 (IL-2) production of T cells, and an upregulation of the IL-2 receptor system. In the present study we examined anti-HBs production after hepatitis B vaccination and the in vitro expression of IL-2 receptors in nondialyzed patients with various degrees of chronic renal failure. Forty-four patients with impaired renal function were immunized with 20 µg recombinant hepatitis B vaccine and boostered after one and six mo…

Viral Hepatitis VaccinesT-LymphocytesReceptor expressionmedicine.disease_causechemistry.chemical_compoundmedicineHumansHepatitis B VaccinesProspective StudiesHepatitis B AntibodiesSeroconversionHepatitis B virusVaccines SyntheticCreatininebiologybusiness.industryVaccinationAntibody titerReceptors Interleukin-2Middle AgedHepatitis Bbiology.organism_classificationVaccinationchemistryHepadnaviridaeNephrologyAntibody FormationImmunologybiology.proteinKidney Failure ChronicAntibodybusinessKidney International
researchProduct

B and T cell immune responses elicited by the BNT162b2 (Pfizer–BioNTech) COVID-19 vaccine in nursing home residents

2021

ABSTRACTObjectivesThe immunogenicity of the BNT162b2 COVID-19 vaccine is understudied in elderly people with comorbidities. We assessed SARS-CoV-2-S-targeted antibody and T cell responses following full vaccination in nursing home residents (NHR).MethodsWe recruited 60 NHR (44 female; median age, 87.5 years), of whom 10 had previously had COVID-19, and 18 healthy controls (15 female; median age, 48.5 years). Pre- and post-vaccination blood specimens were available for quantitation of total antibodies binding RBD and enumeration of SARS-CoV-2-S-reactive IFN-γ CD4+ and CD8+ T cells by flow cytometry.ResultsThe seroconversion rate in presumably SARS-CoV-2 naïve NHR (95.3%), either with or with…

medicine.diagnostic_testbiologybusiness.industryImmunogenicityT cellFlow cytometryVaccinationmedicine.anatomical_structureImmune systemImmunologybiology.proteinMedicineSeroconversionAntibodybusinessCD8
researchProduct

Caveats in interpreting SARS‐CoV‐2 IgM + /IgG − antibody profile in asymptomatic health care workers

2020

Serological testing is increasingly recognized as a useful tool for management of the COVID‐19 pandemic.1 Cross‐sectional serosurveys provide information on exposure levels in a target population, which is helpful for designing public health strategies to blunt community transmission.2 This article is protected by copyright. All rights reserved.

medicine.medical_specialty2019-20 coronavirus outbreakbusiness.industryPublic healthSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Target populationAsymptomaticVirology03 medical and health sciences0302 clinical medicineInfectious DiseasesAntibody ProfileVirologyHealth caremedicine030211 gastroenterology & hepatology030212 general & internal medicinemedicine.symptomSeroconversionbusinessIntensive care medicineJournal of Medical Virology
researchProduct

Parvovirus B19-Associated Microvesicular Eruption

2015

We report on a 3-year-old girl with a microvesicular generalized rash in whom primary infection by parvovirus B19 was demonstrated by seroconversion. To our knowledge, this is the first instance of an eruption arising from parvovirus B19 with this peculiar clinical pattern.

medicine.medical_specialtyGeneralized rashanimal diseasesvirusesRemission SpontaneousErythema InfectiosumSpontaneous remissionDermatologySeverity of Illness Indexhemic and lymphatic diseasesSeverity of illnessParvovirus B19 HumanmedicineHumansSeroconversionbiologyParvovirusbusiness.industryFollow up studiesvirus diseasesExanthemabiology.organism_classificationDermatologyChild PreschoolErythema InfectiosumSkin Diseases ViralPediatrics Perinatology and Child HealthImmunologyFemalebusinessFollow-Up StudiesPediatric Dermatology
researchProduct

Investigation and management of Toxoplasma gondii infection in pregnancy and infancy: a prospective study.

2011

Aim:Toxoplasma gondii infection during pregnancy poses a serious risk to the fetus, therefore timely and accurate diagnosis is essential. The aim of this study was to estimate the frequency of congenital infection via evaluating mother's immunological status and the possibility to improving the diagnostic and therapeutic approaches.Methods:Eighty five mothers with Toxoplasma seroconversion and their offspring were enrolled (among them, 2 spontaneous abortions were documented in the first trimester). Prenatal PCR diagnosis was carried out on 50 patients (60%), with 7 positive cases (14%). Morphological ultrasound scanning revealed anomalies in one fetus. Long-term follow-up included general …

medicine.medical_specialtySettore MED/17 - Malattie InfettiveOffspringToxoplasmosis gondiineurological prognosiToxoplasmosis CongenitalSerologySettore MED/38 - Pediatria Generale E SpecialisticaPregnancyPrenatal DiagnosismedicineHumansPharmacology (medical)Prospective StudiesSeroconversionProspective cohort studyChildPharmacologyFetusPregnancybiologybusiness.industryObstetricsSettore MED/30 - Malattie Apparato Visivoocular prognosiPregnancy OutcomeToxoplasma gondiiGeneral Medicinemedicine.diseasebiology.organism_classificationToxoplasmosisInfectious Disease Transmission Verticalcongenital infectionWestern blot analysisprenatal screeningChild PreschoolPregnancy Complications ParasiticImmunologyserological responseFemaleOriginal ArticlebusinessFollow-Up StudiesActa pharmacologica Sinica
researchProduct